{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-227950","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2024-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.276984+00:00","generated_at":"2026-05-31T01:09:20.824977+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CFO Julie Feder to depart Oct 25; VP Finance Amy Elazzouzi named interim CFO","bullets":["CFO Julie Feder will resign effective Oct 25, 2024; no dispute or disagreement with company.","Feder will provide consulting services through Dec 31, 2024, and receive severance of 10 months base salary.","Amy Elazzouzi, VP Finance, appointed interim principal financial and accounting officer effective Oct 25.","Elazzouzi's annual base salary increased to $360,000; eligible for 30% target bonus.","Company will search for a permanent CFO during the interim period."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-227950","json":"https://secwatch.observer/filing/0001193125-24-227950.json","markdown":"https://secwatch.observer/filing/0001193125-24-227950.md","text":"https://secwatch.observer/filing/0001193125-24-227950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/0001193125-24-227950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/d707178d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:09:20.824977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4889a66e1a","claim":"Amy Elazzouzi was appointed as interim principal financial officer and interim principal accounting officer at Aura Biosciences, Inc..","evidence_excerpt":"On September 25, 2024, the Board of Directors of the Company (the “Board”) designated Amy Elazzouzi, the Company’s Vice President, Finance, as the Company’s interim principal financial officer and interim principal accounting officer, in each case, effective on the Transition Date, to serve in such roles during the pendency of the Company’s search for a new Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/0001193125-24-227950-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal financial officer and interim principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"cb5ccbd72a","claim":"Julie Feder departed as Chief Financial Officer at Aura Biosciences, Inc..","evidence_excerpt":"On September 23, 2024, Julie Feder notified Aura Biosciences, Inc. (the “Company”) of her departure from her role at the Company as an employee and Chief Financial Officer, effective as of October 25, 2024 (the “Transition Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/0001193125-24-227950-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"notified departure"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}